Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Phosphatidylserine-liposomes promote tolerogenic features on dendritic cells in human type 1 diabetes by apoptotic mimicry

  • Rodriguez Fernandez, Silvia
  • Pujol-Autonell, Irma|||0000-0001-6086-4183
  • Brianso, Ferran
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • García Jimeno, Sonia|||0000-0003-3821-2714
  • Villalba Felipe, Adrián|||0000-0003-3148-5453
  • Sánchez, Alex|||0000-0002-8673-7737
  • Aguilera, Eva|||0000-0002-0164-4006
  • Vázquez, Federico|||0000-0001-6493-2374
  • Verdaguer, Joan
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Vives Pi, Marta|||0000-0003-3735-0779
Type 1 diabetes (T1D) is a metabolic disease caused by the autoimmune destruction of insulin-producing β-cells. With its incidence increasing worldwide, to find a safe approach to permanently cease autoimmunity and allow β-cell recovery has become vital. Relying on the inherent ability of apoptotic cells to induce immunological tolerance, we demonstrated that liposomes mimicking apoptotic β-cells arrested autoimmunity to β-cells and prevented experimental T1D through tolerogenic dendritic cell (DC) generation. These liposomes contained phosphatidylserine (PS)-the main signal of the apoptotic cell membrane-and β-cell autoantigens. To move toward a clinical application, PS-liposomes with optimum size and composition for phagocytosis were loaded with human insulin peptides and tested on DCs from patients with T1D and control age-related subjects. PS accelerated phagocytosis of liposomes with a dynamic typical of apoptotic cell clearance, preserving DCs viability. After PS-liposomes phagocytosis, the expression pattern of molecules involved in efferocytosis, antigen presentation, immunoregulation, and activation in DCs concurred with a tolerogenic functionality, both in patients and control subjects. Furthermore, DCs exposed to PS-liposomes displayed decreased ability to stimulate autologous T cell proliferation. Moreover, transcriptional changes in DCs from patients with T1D after PS-liposomes phagocytosis pointed to an immunoregulatory prolife. Bioinformatics analysis showed 233 differentially expressed genes. Genes involved in antigen presentation were downregulated, whereas genes pertaining to tolerogenic/anti-inflammatory pathways were mostly upregulated. In conclusion, PS-liposomes phagocytosis mimics efferocytosis and leads to phenotypic and functional changes in human DCs, which are accountable for tolerance induction. The herein reported results reinforce the potential of this novel immunotherapy to re-establish immunological tolerance, opening the door to new therapeutic approaches in the field of autoimmunity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Liposome-based immunotherapy against autoimmune diseases, Therapeutic effect on multiple sclerosis

  • Pujol-Autonell, Irma|||0000-0001-6086-4183
  • Mansilla Lopez, Maria Jose|||0000-0002-5044-6313
  • Rodríguez Fernández, Silvia
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Navarro-Barriuso, Juan|||0000-0003-2884-4961
  • Ampudia Carrasco, Rosa María|||0000-0002-0734-0433
  • Rius, Aleix
  • García Jimeno, Sonia|||0000-0003-3821-2714
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Vives Pi, Marta|||0000-0003-3735-0779
Based on the ability of apoptosis to induce immunological tolerance, liposomes were generated mimicking apoptotic cells, and they arrest autoimmunity in Type 1 diabetes. Our aim was to validate the immunotherapy in other autoimmune disease: multiple sclerosis. Materials & methods: Phosphatidylserine-rich liposomes were loaded with disease-specific autoantigen. Therapeutic capability of liposomes was assessed in vitro and in vivo. Results: Liposomes induced a tolerogenic phenotype in dendritic cells, and arrested autoimmunity, thus decreasing the incidence, delaying the onset and reducing the severity of experimental disease, correlating with an increase in a probably regulatory CD25+ FoxP3- CD4+ T-cell subset. Conclusion: This is the first work that confirms phosphatidylserine-liposomes as a powerful tool to arrest multiple sclerosis, demonstrating its relevance for clinical application.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impaired Phagocytosis in Dendritic Cells From Pediatric Patients With Type 1 Diabetes Does Not Hamper Their Tolerogenic Potential

  • Rodríguez Fernández, Silvia
  • Murillo-Vallés, Marta|||0000-0002-3208-2982
  • Villalba Felipe, Adrián|||0000-0003-3148-5453
  • Perna-Barrull, David|||0000-0003-2079-818X
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Gómez Muñoz, Laia|||0000-0001-9640-6213
  • Aguilera, Eva|||0000-0002-0164-4006
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Vázquez, Federico|||0000-0001-6493-2374
  • Bel, Joan|||0000-0002-3577-6322
  • Vives Pi, Marta|||0000-0003-3735-0779
Type 1 diabetes (T1D) is prompted by defective immunological tolerance, an event in which dendritic cells (DCs) are crucial as immune response orchestrators. In fact, they contribute to maintaining tolerance to self-antigens, but they can also prompt an immunogenic response against them, leading to autoimmunity. Countless factors can potentially impact on the proper functionality of the DCs, which range from altered subset distribution, impaired phagocytic function to abnormal gene expression. Moreover, in T1D, metabolic dysregulation could impair DC functions as well. Indeed, since T1D clinical course is likely to be more aggressive in children and adolescents and entails severe dysglycemia, the aim of this study was to analyze circulating DCs subpopulations in pediatric T1D at different stages, as well as to characterize their phagocytosis ability and tolerance induction potential. Thus, pediatric patients newly diagnosed with T1D, with established disease and control subjects were recruited. Firstly, DCs subsets from peripheral blood were found quantitatively altered during the first year of disease, but recovered in the second year of progression. Secondly, to study the tolerogenic functionality of DCs, liposomes with phosphatidylserine (PS) were designed to mimic apoptotic beta cells, which are able to induce tolerance, as previously demonstrated by our group in DCs from adult patients with T1D. In this study, monocyte-derived DCs from pediatric patients with T1D and control subjects were assessed in terms of PS-liposomes capture kinetics, and transcriptional and phenotypic changes. DCs from pediatric patients with T1D were found to phagocyte PS-liposomes more slowly and less efficiently than DCs from control subjects, inversely correlating with disease evolution. Nonetheless, the transcription of PS receptors and immunoregulatory genes, cytokine profile, and membrane expression of immunological markers in DCs was consistent with tolerogenic potential after PS-liposomes phagocytosis. In conclusion, T1D progression in childhood entails altered peripheral blood DCs subsets, as well as impaired DCs phagocytosis, although tolerance induction could still function optimally. Therefore, this study provides useful data for patient follow-up and stratification in immunotherapy clinical trials.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prenatal Betamethasone interferes with immune system development and alters target cells in autoimmune diabetes

  • Perna-Barrull, David|||0000-0003-2079-818X
  • Rodríguez-Fernández, Silvia|||0000-0001-8429-4293
  • Pujol-Autonell, Irma|||0000-0001-6086-4183
  • Gieras, Anna|||0000-0002-5147-2281
  • Ampudia Carrasco, Rosa María|||0000-0002-0734-0433
  • Villalba Felipe, Adrián|||0000-0003-3148-5453
  • Glau, Laura
  • Tolosa, Eva|||0000-0002-5247-8378
  • Vives Pi, Marta|||0000-0003-3735-0779
Non-genetic factors are crucial in the pathogenesis of type 1 diabetes (T1D), a disease caused by autoimmunity against insulin-producing β-cells. Exposure to medications in the prenatal period may influence the immune system maturation, thus altering self-tolerance. Prenatal administration of betamethasone -a synthetic glucocorticoid given to women at risk of preterm delivery- may affect the development of T1D. It has been previously demonstrated that prenatal betamethasone administration protects offspring from T1D development in nonobese diabetic (NOD) mice. The direct effect of betamethasone on the immature and mature immune system of NOD mice and on target β-cells is analysed in this paper. In vitro, betamethasone decreased lymphocyte viability and induced maturation-resistant dendritic cells, which in turn impaired γδ T cell proliferation and decreased IL-17 production. Prenatal betamethasone exposure caused thymus hypotrophy in newborn mice as well as alterations in immune cells subsets. Furthermore, betamethasone decreased β-cell growth, reduced C-peptide secretion and altered the expression of genes related to autoimmunity, metabolism and islet mass in T1D target tissue. These results support the protection against T1D in the betamethasone-treated offspring and demonstrate that this drug alters the developing immune system and β-cells. Understanding how betamethasone generates self-tolerance could have potential clinical relevance in T1D.